Last reviewed · How we verify
Oxycodone(single compound)
Oxycodone binds to opioid receptors in the central nervous system to block pain signal transmission and produce analgesia.
Oxycodone binds to opioid receptors in the central nervous system to block pain signal transmission and produce analgesia. Used for Moderate to severe acute pain, Moderate to severe chronic pain.
At a glance
| Generic name | Oxycodone(single compound) |
|---|---|
| Also known as | Oxycontin |
| Sponsor | Mundipharma Korea Ltd |
| Drug class | Opioid analgesic |
| Target | Mu (μ) opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Oxycodone is a semi-synthetic opioid agonist that acts primarily on mu (μ) opioid receptors in the brain and spinal cord. By binding to these receptors, it inhibits the release of neurotransmitters involved in pain perception and modulates pain signaling pathways. This results in pain relief and can also produce euphoria, which contributes to its potential for abuse and dependence.
Approved indications
- Moderate to severe acute pain
- Moderate to severe chronic pain
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Vomiting
- Pruritus
- Respiratory depression
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxycodone(single compound) CI brief — competitive landscape report
- Oxycodone(single compound) updates RSS · CI watch RSS
- Mundipharma Korea Ltd portfolio CI